12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cimzia certolizumab pegol: Additional Phase II/III data

Additional data from the double-blind, Japanese Phase II/III J-RAPID trial in 316 patients who had an inadequate response to methotrexate showed that 100, 200 and 400 mg Cimzia every 2 weeks as an add-on to methotrexate each significantly improved ACR20 response rate, the primary endpoint, at weeks 12 and 24 vs. placebo plus methotrexate (p<0.001 for...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >